Canine IL-13 receptor alpha-1 subunit nucleic acid molecules

Details Canine IL-13 receptor alpha-1 subunit nucleic acid molecules Canine IL-13 receptor alpha-1 subunit nucleic acid molecules

2008-05-27

2008-05-27

Spector, Lorraine (Department: 1647)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S069100, C435S069700, C435S320100, C536S023500, C536S024500, C530S350000, C530S387300

Reexamination Certificate

active

10753159

ABSTRACT:
The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present invention discloses nucleic acid molecules encoding canine IgG, including species-specific regions of the heavy chain of canine IgG, and canine IL-13R alpha chain (IL-13Rα) proteins, particularly canine interleuken receptor alpha 1 (IL-13Rα1) and canine interleuken receptor alpha 2 (IL-13Rα2) proteins. Also included are canine IgG and IL-13Rα proteins, antibodies having selectivity for such proteins, inhibitors of such proteins and/or nucleic acid molecules, cells transformed with said nucleic acid molecules, assays employing such cells, nucleic acids molecules, proteins, antibodies and/or inhibitors, and therapeutic compositions comprising said nucleic acids molecules, proteins, antibodies and/or inhibitors. Also included are kits containing said molecules or chimera thereof, including their use to evaluate and regulate an immune response in an animal.

REFERENCES:
patent: 5593861 (1997-01-01), Maeda et al.
patent: 5596072 (1997-01-01), Culpepper et al.
patent: 5614191 (1997-03-01), Puri et al.
patent: 5622842 (1997-04-01), Hollis et al.
patent: 5629415 (1997-05-01), Hollis et al.
patent: 5652123 (1997-07-01), Caput et al.
patent: 5696234 (1997-12-01), Zurawski et al.
patent: 5710023 (1998-01-01), Collins et al.
patent: 5783181 (1998-07-01), Browne et al.
patent: 5830453 (1998-11-01), Badr et al.
patent: 5852183 (1998-12-01), Maeda et al.
patent: 5858347 (1999-01-01), Bauer et al.
patent: 5919456 (1999-07-01), Puri et al.
patent: 5935824 (1999-08-01), Sgarlato
patent: 2002/0137139 (2002-09-01), Byatt et al.
patent: 4-40894 (1992-02-01), None
patent: WO 97/20926 (1997-06-01), None
patent: WO 97/31946 (1997-09-01), None
patent: WO 98/08957 (1998-03-01), None
patent: WO 98/10638 (1998-03-01), None
J.A. Wells, “Additivity of mutational effects in proteins”, 1990, Biochemistry 29:8509-8517.
J.T. Ngo et al., Computational complexitiycomplexity, protein structure prediction, and the Levinthal Paradox, Chapter 14 in The protein folding problem and tertiary structure prediction, K. Merz, Jr. Ed., Birkhauser, Boston, 1994. pp. 492-495.
P. Bork, “Powers and pitfalls in sequence analysis: The 70% hurdle”, Genome Research 10:398-400, 2000.
J. Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era”, Trends in Biotech 18(1):34-39, 2000.
T. Doerks et al., “Protein annotation: detective work for function prediction”, Trends in Genetics, 4(g):248-250, Jun. 1998.
T.F. Smith et al., The challenges of genome sequence annotation or “The devil is in the details”, Nature Biotechnology 15:1222-1223, 1997.
S.E. Brenner, “Errors in genome annotation”, Trends in Genetics 15(4) 132-133, 1999.
P. Bork, “Go hunting in sequence databases but watch out for the traps”, Trends in Genetics 12(10):425-426, 1996.bv.
Ashkenazi et al.,Current Opinion in Immunology, 1997, vol. 9, pp. 195-200.
Capon et al.,Nature, 1989, vol. 337, pp. 525-531.
Day et al.,Research in Veterinary Science, 1996, vol. 61, pp. 136-142.
Day et al.,Research in Veterinary Science, 1995, vol. 58, pp. 82-89.
Hayden et al.,Current Opinion in Immunology, 1997, vol. 9, pp. 201-212.
Johnson et al.,The Journal of Immunology, 1967, vol. 98, No. 5, pp. 935-940.
Mazza et al.,Research in Veterinary Science, 1994, vol. 57, pp. 133-139.
Mazza et al.,Journal of Immunological Methods, 1993, vol. 161, pp. 193-203.
Schur, Peter H. MD,Annals of Allergy, 1987, vol. 58, pp. 89-101.
Avery, et al., Sequence Submission, 1998, Accession No. AF067449.
Avery, et al., Sequence Submission, 1998, Accession No. AF067450.
Avery, et al., Sequence Submission, 1998, Accession No. AF067451.
Avery, et al., Sequence Submission, 1998, Accession No. AF067452.
Avery, et al., Sequence Submission, 1998, Accession No. AF067453.
Avery, et al., Sequence Submission, 1998, Accession No. AF079118.
Avery, et al., Sequence Submission, 1998, Accession No. AF079119.
Avery, et al., Sequence Submission, 1998, Accession No. AF079120.
Avery, et al., Sequence Submission, 1998, Accession No. AF079121.
Avery, et al., Sequence Submission, 1998, Accession No. AF079122.
Avery, et al., Sequence Submission, 1998, Accession No. AF079123.
Redpath, et al., 1998,Human Immunology, vol. 59, pp. 720-727.
DeBoer, et al., 1993,Veterinary Immunology and Immunopathology, vol. 37, No. 3-4, pp. 183-199.
Callard, et al., 1996,Immunology Today, vol. 17, No. 3, pp. 108-110 (XP002010895).
Tang, et al., 2001,Journal of Allergy and Clinical Immunology, vol. 107, No. 2, abstract, p. S91 (XP001030691).

Affiliated with

Also associated with

Rating

Canine IL-13 receptor alpha-1 subunit nucleic acid molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Canine IL-13 receptor alpha-1 subunit nucleic acid molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Canine IL-13 receptor alpha-1 subunit nucleic acid molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3916945